Tony Anderson

ID Pharmacist @SylvesterCancer @univmiami | @YNHH ID PGY2 alum

[Lisa Dumkow @LisaIDpharmD]

It’s official! 🎉 New name, same amazing organizations. The Antimicrobials meeting is coming to Baltimore, MD in May 2027 by @MAD_ID_ASP & @SIDPharm! #MADIDxSIDP2026

[Dayna McManus @Day_Mac3]

🚨 🚨 We are recruiting for a PGY2 Pharmacy Resident in Infectious Diseases @YNHH in New Haven, CT.

Learn more by joining one of our open houses. Register: https://t.co/HKHQxrePux or QR below and zoom link will be emailed prior to the session.

[Ryan Feldman (empoisonpharmd.bsky.social) @EMPoisonPharmD]

Nice effort to make a useful infographic to help patients

Might have been a good idea to you know, include a pharmacist who does this multiple times per day for their input as well....

oh wait this is the AMA's journal, how do they feel about pharmacists again?

[Maria Alejandra Mendoza, MD @MariAleMendozaD]

Would everyone benefit from extended letermovir prophylaxis after day100? Here we discuss risk factors for delayed csCMVi in a retrospective study at @MayoClinicINFD @RazonableMD @MayoHemeOnc

https://t.co/hgRHRuOdIV

[Raymund Razonable @RazonableMD]

Management of resistant and refractory cytomegalovirus infections after transplantation: Expert Review of Anti-infective Therapy https://t.co/s6GNdjjA5b

[Michael Ison, MD MS @MichaelGIsonMD]

Please join ESGICH for our first session of our Webinar Series on September 24 at 12pm CET/8pm Melbourne/6am EST. This webinar will focus on Stewardship in ICHs.

Chairs: @AbbyPDouglas & Mark DeBoer
Talks by: @TrubianoJason, @mularoni & Dr. Milkulska

https://t.co/QUezXtPgOj

[Camille Nelson Kotton @KottonNelson]

Excited to have the newest version published - appreciate the teamwork with many including ⁦@RazonableMD⁩ ⁦@ChemalyRoy ⁦@NatoriYoichiro⁩ - Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients https://t.co/D5cPub204v

[SIDP @SIDPharm]

📰 Extra! Extra! Read all about the 2024 updates to the IDSA Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Below are highlights from the Notable Updates from 2023 section. For more info: https://t.co/lfiGWbqo6y
#AntimicrobialResistance #IDTwitter

[MSGERC @MSG_ERC]

🆕 Antifungal TDM toolkit

Download the infographics here: https://t.co/gsf2Mlpewd

[Mihalis Lionakis @LionakisLab]

BTK is known for its role in BCR signaling & BTKi transformed the therapy of lymphoid malignancies. But why do BTKi cause fungal disease? We show that BTK drives neutrophil antifungal activity via p40phox and RAC2 activation; GMCSF rescues BTKi PMN defects
https://t.co/q3olu7NUvd

[Joshua Hill, MD @JoshuaHillMD]

In this study, we estimate the incidence of HHV-6 reactivation and encephalitis after CAR T. @ErikaKampouri @drjgauthier
HHV-6 Reactivation and Disease Are Infrequent in Chimeric Antigen Receptor T-cell Therapy Recipients
https://t.co/c0bPF92MP1

[Letstalkmicro @Letstalkmicro1]

Happy Friday! A new episode is now available. @IDstewardship joins the podcast to talk about antimicrobial stewardship, antibiograms and more. I also ask him if he has a favorite organism. Download it today! Link in comments.

#microbiology #medlabsci #podcast #IDtwitter #Friday

[Dayna McManus @Day_Mac3]

🚨 Join our #IDteam @ynhhealth ! We have an additional opening for a multi-specialty #IDpharmacist for @YNHH 🦠🔬

Message me for more info or apply here 👇: https://t.co/pbeaccNa2G

@omattacycline
@abripenem
@emweisz
@YaleIDFellows
@SIDPharm
@accpinfdprn

[Sonali Advani MD, MPH, FIDSA @Sonali_Advani]

‼️New in @JAMANetworkOpen w @HMS_MI: Risk of bacteremia in hospitalized adults with #ASB

Key findings:
In patients with #ASB, bacteremia from a presumed urinary source was rare:
~1.4% overall
<1% in #AMS
<1% in #AMS + #dementia
~3% if signs of sepsis

📰:https://t.co/5UJO7FR9yX

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🆕️🔥Cohort study
In this 5-year, 68-hospital cohort study of 11 590 hospitalized patients with asymptomatic bacteriuria, only 1.4% developed bacteremia from a presumed urinary source, while 72.2% received empiric antibiotic therapy for UTI #IDXposts
https://t.co/347SRl7v91

[SIDP @SIDPharm]

🆕Episode of #Breakpoints:

Dr. Ajit Limaye & Dr. Camille Kotton (@KottonNelson) join Dr. Erin McCreary (@ErinMcCreary) to discuss fascinating updates in the CMV space including new RCTs for prevention, vaccines, & more! Learn why a little "hair of the dog" might be a good thing.

[Jill Lykon, PharmD, BCOP @JillLykon]

Going to #ASHP Midyear 2023 - Come meet with us to hear about our open Clinical Oncology Pharmacist Positions (INP & OP Hematology, SCT, and OP Oncology) @UMiamiHealth @SylvesterCancer 🙌 https://t.co/DjoXFxA1qr

[Erin McCreary @ErinMcCreary]

✅ RCT data shows no difference in AKI btwn TZP+ VAN vs FEP+VAN

✅ “authors provide a roadmap for such embedded randomised clinical trials”

the coolest thing about ACORN is the fact that they did it. learning while doing!!

@syctong @JAMA_current
https://t.co/NffzwhRLJP

[Dr Roy Chemaly @ChemalyRoy]

I think we are almost there to use this tool at the bedside!!! We are working with a group of experts in SOT and HCT to come up with some recs @KottonNelson

[SIDP @SIDPharm]

🆕 Episode of #Breakpoints:
You may ❤️ it. You may hate it. You may think it’s the equivalent of doing your own taxes (hi, @IDdocAdi), but this episode is all about SMX/TMP! @emilylheil & @AFratty join @thejillianhayes to unpack the data in this space

🎧 https://t.co/XTxayI4EF8